FAQ: HeartBeam Inc. Study on 3D ECG System Accuracy Compared to Standard 12-Lead ECG
Summary
What is the main finding of the HeartBeam study?
The study showed no significant differences in detecting atrial fibrillation, atrial flutter, and sinus rhythm between HeartBeam’s deep learning algorithms applied to their system versus standard 12-lead ECGs, with accuracy rates of 94.5% for HeartBeam and 95.5% for standard 12-lead.
Why is this study significant for cardiac care?
The findings highlight the potential of HeartBeam’s compact, 3D device to expand advanced cardiac monitoring to settings where full 12-lead ECGs may be impractical, making cardiac care more accessible outside traditional medical facilities.
How does HeartBeam’s technology work?
HeartBeam’s technology is the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG, designed for portable use wherever the patient is located.
Who presented the study results and where?
Dr. Joshua Lampert of Mount Sinai Heart presented the data from 201 patients at HRX Live 2025 in Atlanta, demonstrating the comparable accuracy between the two systems.
What are the regulatory statuses of HeartBeam’s technologies?
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, while the 12-Lead ECG synthesis software is currently under FDA review.
How does HeartBeam’s accuracy compare to standard 12-lead ECGs?
The study showed comparable accuracy with HeartBeam achieving 94.5% accuracy versus 95.5% for standard 12-lead ECGs in detecting atrial fibrillation, atrial flutter, and sinus rhythm.
What are the practical applications of HeartBeam’s technology?
The technology enables physicians to identify cardiac health trends and acute conditions outside medical facilities, allowing for portable ECG monitoring and directing patients to appropriate care wherever they are located.
Where can investors find more information about HeartBeam?
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT, and the full press release can be viewed at https://ibn.fm/BDiIa.
What intellectual property does HeartBeam hold?
HeartBeam holds over 20 issued patents related to technology enablement, protecting their innovative 3D ECG and 12-lead synthesis capabilities.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 200537